Tender Details

Country: Hungary
Summary: Has Used in Systemic, Inflammatory Pathology
HUT Ref No: 92440958
Deadline: 24 Nov 2023
Financier: Self Financed
Purchaser Ownership: Government
Tender Value: Refer Document
Notice Type: Tender
Document Ref. No.: 704582-2023
Purchaser's Detail:
Login to see full purchaser details. Login to see full purchaser details. Login to see full purchaser details. Login to see full purchaser details. Login to see full purchaser details. Login to see full purchaser details. Login to see full purchaser details. Login to see full purchaser details. Login to see full purchaser details.
Login to see details
Description:
Purchase of active substances used in inflammatory pathologies subject to batch accounting for a period of 24 months active and 4 months passive for the conclusion of a framework agreement. within the framework of the open procedure according to § 105, paragraph (1), point a), an additional 12 months of the active period of the Framework Agreementpos. with the possibility of extension.
Subject and quantity of this public procurement procedure (per part):
1. part: active substance baricitinib (OENO: 06069): 1,170,260 mg base amount, option 585,130 mg, total frame amount: 1,755,390 mg
2. part: active ingredient tofacitinib (OENO: 06070): 2,625,280 mg basicquantity 1,312,640 mg option, total frame quantity: 3,937,920 mg
3. part: active substance ustekinumab (OENO: 06056): 686,070 mg base amount 343,035 mg option, total frame amount: 1,029,105 mg
4. part: active substance vedolizumab (OENO: 06005): 1,883,400 mg basic amount 941,700 mg option, full frameamount: 2,825,100 mg
5. part: active substance ixekizumab (OENO: 06068): 669,760 mg base amount 334,880 mg option, total frame amount: 1,004,640 mg
6. part: active substance guselkumab (OENO: 06074): 387,800 mg base amount 193,900 mg option, total frame amount: 581,700 mg
Affected patient group: the procuredAll patients are treated in all departments with active ingredients.
Place of execution: Decree 9/1993 (IV. 2.) NM 1/A. Institutional range separated by active substance and indication included in Annex no.
Baricitinib, tofacitinib, ustekinumab, vedolizumab, guselkumab hatoany...
Documents:

If you are registered member, kindly login to view full details of this tender notice:

Has Used in Systemic, Inflammatory Pathology - Hungary Tender

The NATIONAL HEALTH INSURANCE FUND MANAGER, a Government sector organization in Hungary, has announced a new tender for Has Used in Systemic, Inflammatory Pathology. This tender is published on HungaryTenders under HUT Ref No: 92440958 and is categorized as a Tender. Interested and eligible suppliers are invited to participate by reviewing the tender documents and submitting their bids before the deadline on 2023-11-24.

The estimated tender value is Refer Document, and full details, including technical specifications and submission requirements, are provided in the official tender documents. Ensure all submissions meet the criteria outlined to be considered for evaluation.